Zimmer Biomet Holdings (XSWX:ZBH) NonCurrent Deferred Liabilities: CHF197 Mil (As of Mar. 2026)


XSWX:ZBH Zimmer Biomet Holdings Inc XSWX:ZBH
72 GF Score
Price CHF71.50
GF Value CHF101.16
! 3 Warning Signs
View Full Analysis

What is Zimmer Biomet Holdings NonCurrent Deferred Liabilities?

Zimmer Biomet Holdings XSWX:ZBH -1.38% 72 NonCurrent Deferred Liabilities is CHF197 Mil as of Mar. 2026. GuruFocus rates XSWX:ZBH with a GF Score™ of 72/100 and a GF Value™ of CHF101.16. The stock has 3 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Zimmer Biomet Holdings's non-current deferred liabilities for the quarter that ended in Mar. 2026 was CHF197 Mil.

Zimmer Biomet Holdings NonCurrent Deferred Liabilities Related Terms

Zimmer Biomet Holdings NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Zimmer Biomet Holdings's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zimmer Biomet Holdings NonCurrent Deferred Liabilities Chart

Zimmer Biomet Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 514.38 442.32 309.25 314.29 194.52

Zimmer Biomet Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 194.52 196.75
XSWX:ZBH
72GF Score
Zimmer Biomet Holdings Inc XSWX:ZBH
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of CHF197 Mil mean?
Zimmer Biomet Holdings (XSWX:ZBH) has a NonCurrent Deferred Liabilities of CHF197 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Zimmer Biomet Holdings and its competitors.
Is Zimmer Biomet Holdings' NonCurrent Deferred Liabilities too high?
Zimmer Biomet Holdings' current NonCurrent Deferred Liabilities is CHF197 Mil. Overall, Zimmer Biomet Holdings has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' NonCurrent Deferred Liabilities compare to STE and PEN?
Zimmer Biomet Holdings' NonCurrent Deferred Liabilities of CHF197 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Medical Devices & Instruments company?
A good NonCurrent Deferred Liabilities depends on the Medical Devices & Instruments industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Zimmer Biomet Holdings and its competitors. Zimmer Biomet Holdings's current NonCurrent Deferred Liabilities is CHF197 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Zimmer Biomet Holdings (XSWX:ZBH) has a current NonCurrent Deferred Liabilities of CHF197 Mil. The stock's GF Value™ is CHF101.16, compared to a current price of CHF71.50 — trading 29.3% below its estimated fair value. The current NonCurrent Deferred Liabilities is CHF197 Mil. Zimmer Biomet Holdings' overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Zimmer Biomet Holdings (XSWX:ZBH), the current NonCurrent Deferred Liabilities is CHF197 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zimmer Biomet Holdings (XSWX:ZBH) Overvalued in 2026?

Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued. The current stock price of CHF71.50 is trading 29.3% below its estimated GF Value™ of CHF101.16.

Key valuation signals for XSWX:ZBH:

  • NonCurrent Deferred Liabilities: CHF197 Mil
  • GF Value™: CHF101.16 vs. price of CHF71.50 (29.3% below fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the XSWX:ZBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zimmer Biomet Holdings Business Description

Address 345 East Main Street, Warsaw, IN, USA, 46580
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
72GF Score

Get the complete analysis for XSWX:ZBH

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF71.50
Price
CHF101.16
GF Value